13F Holdings
中文EN

AXSM Axsome Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1579428 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY54.2%
TTM net income YoY31.5%
TTM EPS YoY35.1%
Revenue 3-yr CAGR57.0%
Net income 3-yr CAGR—

Margins

Gross margin93.2%
Operating margin-17.5%
Net margin-18.2%
FCF margin-9.5%
EBITDA margin-17.4%

Returns

ROE-175.6%
ROA-21.0%
ROIC (approx.)—
Asset turnover1.16x

Leverage & solvency

Liabilities / assets87.2%
Debt / equity1.78x
Current ratio1.42x
Interest coverage22.43x

Cash quality & payout

Operating cash flow / net income0.52x
Accruals ratio-10.1%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$638.50M$385.69M$270.60M$50.04M—
Cost of revenue$47.48M$33.30M$26.07M$5.20M—
Gross profit$591.02M$352.39M$244.53M$44.84M—
R&D expense$183.28M$187.08M$97.94M$57.95M$58.06M
SG&A expense$570.60M$411.36M$323.12M$159.25M$66.65M
Operating income-$166.76M-$280.56M-$231.82M-$179.80M-$124.71M
Interest expense-$15.93M-$21.58M-$20.03M-$9.66M—
Pretax income-$183.70M-$287.13M-$238.28M-$187.13M-$130.40M
Income tax-$530,000$85,000$960,000$0$0
Net income-$183.17M-$287.22M-$239.24M-$187.13M-$130.40M
EBITDA-$166.26M-$280.03M-$231.37M-$179.54M-$124.63M
EPS (basic)-3.68-5.99-5.27-4.60-3.47
EPS (diluted)-3.68-5.99-5.27-4.60-3.47
Weighted avg. shares (diluted)49.75M47.91M45.43M40.66M37.62M
Balance sheet
Cash & equivalents$322.93M$315.35M$386.19M$200.84M$86.47M
Receivables$224.46M$142.00M$94.82M$37.70M—
Inventory$27.94M$15.73M$15.13M$4.32M—
Current assets$588.99M$485.06M$504.26M$245.64M$86.52M
PP&E, net$562,000$584,000$846,000$722,000$283,846
Goodwill$12.04M$12.04M$12.04M$10.31M—
Intangibles$40.52M$46.89M$53.29M$59.66M—
Total assets$689.80M$568.50M$588.24M$331.48M$87.79M
Current liabilities$378.84M$230.10M$138.85M$96.56M$23.07M
Short-term debt$70.00M$0———
Long-term debt$117.75M$180.71M$178.07M$94.26M$49.09M
Total debt$187.75M$180.71M$178.07M$94.26M$49.09M
Total liabilities$601.51M$511.48M$397.26M$221.92M$72.15M
Shareholders' equity$88.30M$57.02M$190.98M$109.56M$15.63M
Net debt-$135.19M-$134.64M-$208.12M-$106.58M-$37.38M
Shares outstanding50.88M48.67M47.35M43.50M37.82M
Cash flow statement
Operating cash flow-$93.41M-$128.41M-$145.08M-$116.51M-$108.23M
Capital expenditure$480,000$270,000$582,000$702,000$308,000
Free cash flow-$93.89M-$128.68M-$145.66M-$117.21M-$108.53M
Investing cash flow-$480,000-$270,000-$582,000-$53.70M-$308,000
Financing cash flow$101.47M$57.84M$331.01M$284.58M$11.13M
Depreciation & amortization$503,000$532,000$459,000$263,000$76,000
Stock-based compensation$93.75M$85.22M$62.62M$37.73M$20.80M

Free plan shows the latest 5 periods; Pro shows all 12 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.